Industry’s reaction to Union Budget 2024-25

Indian Pharma Post brings together the views of industry leaders on the Interim Union Budget 2024-25 announcement and its impact on the industry

Lupin Digital Health introduces digital therapeutics certificate for Cardiologists in India in collaboration with ACC

Ascletis announces dosing of the first patient in Phase III clinical trial of ASC40

This Phase III clinical trial is a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and efficacy of ASC40

Glenmark, Ichnos Sciences form ‘Ichnos Glenmark Innovation’ for new drug discovery in cancer treatment

This alliance brings together drug innovation capabilities of Glenmark and Ichnos to develop cutting-edge therapies for the treatment of hematological malignancies and solid tumors

Merck’s Keytruda reduced the risk of death by 38% for patients with RCC

Keynote -564 is the first Phase 3 trial to demonstrate superior overall survival (OS) with adjuvant therapy compared to placebo in patients with RCC

Syngene Q3 FY 24 PAT up 4% to Rs 115 Cr

For 9 months period ended December 2023, the company’s PAT up 16% to Rs 330 crores (before exceptional items)

Aster DM Healthcare gets shareholders nod to separate the GCC business

The company also plans to boost its India presence by adding 1,500 beds in the next 2-3 years

Health Minister Mandaviya inaugurates NIPER in Guwahati

Lays foundation stone of NIPER Hyderabad and NIPER Raebareli

Aarti Pharmalabs sets up R&D Centre in Navi Mumbai

The R&D centre is mainly dedicated to the Process R&D of New Chemical Entities (NCE) development projects

BioAsia 2024 to focus on data and AI for life sciences

The three-day forum will feature global leaders, scientists, regulatory body representatives, industry associations, and academia among many others